Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Int J Mol Sci ; 25(2)2024 Jan 19.
Article in English | MEDLINE | ID: mdl-38279218

ABSTRACT

The positive effects of physical exercise (EX) are well known to be mediated by cerebral BDNF (brain-derived neurotrophic factor), a neurotrophin involved in learning and memory, the expression of which could be induced by circulating irisin, a peptide derived from Fibronectin type III domain-containing protein 5 (FNDC5) produced by skeletal muscle contraction. While the influence of EX modalities on cerebral BDNF expression was characterized, their effect on muscle FNDC5/Irisin expression and circulating irisin levels remains to be explored. The present study involved Wistar rats divided into four experimental groups: sedentary (SED), low- (40% of maximal aerobic speed, MAS), intermediate- (50% of MAS) and high- (70% of MAS) intensities of treadmill EX (30 min/day, 7 days). Soleus (SOL) versus gastrocnemius (GAS) FNDC5 and hippocampal BDNF expressions were evaluated by Western blotting. Additionally, muscular FNDC5/Irisin localization and serum/hippocampal irisin levels were studied by immunofluorescence and ELISA, respectively. Our findings revealed that (1) serum irisin and hippocampal BDNF levels vary with EX intensity, showing a threshold intensity at 50% of MAS; (2) hippocampal BDNF levels positively correlate with serum irisin but not with hippocampal FNDC5/Irisin; and (3) GAS, in response to EX intensity, overexpresses FNDC5/Irisin in type II muscle fibers. Altogether, peripheral FNDC5/Irisin levels likely explain EX-dependent hippocampal BDNF expression.


Subject(s)
Brain-Derived Neurotrophic Factor , Fibronectins , Rats , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Fibronectins/metabolism , Rats, Wistar , Transcription Factors/metabolism , Muscle, Skeletal/metabolism
2.
Sci Total Environ ; 861: 160600, 2023 Feb 25.
Article in English | MEDLINE | ID: mdl-36470378

ABSTRACT

Cover cropping is commonly acknowledged to promote soil health in agriculture. However, contradictory findings on the benefits of cover crops for soil health, crop productivity, economic and ecological factors, as well as the influence of inherent soil parameters on such benefits exist in the scientific literature. Here, we critically assessed evidence of cover crop benefits through a systematic review of the published literature. To access relevant papers, we searched the literature for cover crops and soil health indicators using Scopus (1996-2020), ScienceDirect (1996-2020) and Google scholar (1970-1996) with specific keywords and combinations. Only English research papers including experimental plots and control groups were considered. We analyzed 102 unique peer-reviewed papers and 1494 corresponding unique plots encompassing various cover crops, soil textures, climates, management systems and experimental duration (1-3 years, 4-6 years, 7-10 years and over 10 years). Strong evidence suggests that cover crops can enhance soil structure and promote soil health by improving soil physical and chemical properties, including saturated hydraulic conductivity (mean net change of 105.6 %), total organic carbon (10.1 %), and total nitrogen (20.2 %). On the other hand, cover crops exhibit weak effects on properties like bulk density and microporosity with fairly low values of net change. In most cases, cover crops increase the soil carbon content, including microbial biomass carbon (19.5 %) and particulate organic carbon (49.5 %). In this systematic review, we found limited studies on the effect of cover crops on soil health as influenced by soil texture, regional climate, rainfall and duration of the cover crop practices. The paucity of long-term regional systematic research of soil physics, chemistry and biology makes it difficult to forecast future implications of cover crops on soil health indicators.


Subject(s)
Agriculture , Soil , Soil/chemistry , Crop Production , Crops, Agricultural , Carbon
3.
J Gastroenterol ; 56(5): 442-455, 2021 05.
Article in English | MEDLINE | ID: mdl-33782752

ABSTRACT

BACKGROUND: We previously showed that supernatants of Lactobacillus biofilms induced an anti-inflammatory response by affecting the secretion of macrophage-derived cytokines, which was abrogated upon immunodepletion of the stress protein GroEL. METHODS: We purified GroEL from L. reuteri and analysed its anti-inflammatory properties in vitro in human macrophages isolated from buffy coats, ex vivo in explants from human biopsies and in vivo in a mouse model of DSS induced intestinal inflammation. As a control, we used GroEL purified (LPS-free) from E. coli. RESULTS: We found that L. reuteri GroEL (but not E. coli GroEL) inhibited pro-inflammatory M1-like macrophages markers, and favored M2-like markers. Consequently, L. reuteri GroEL inhibited pro-inflammatory cytokines (TNFα, IL-1ß, IFNγ) while favouring an anti-inflammatory secretome. In colon tissues from human biopsies, L. reuteri GroEL was also able to decrease markers of inflammation and apoptosis (caspase 3) induced by LPS. In mice, we found that rectal administration of L. reuteri GroEL (but not E. coli GroEL) inhibited all signs of haemorrhagic colitis induced by DSS including intestinal mucosa degradation, rectal bleeding and weight loss. It also decreased intestinal production of inflammatory cytokines (such as IFNγ) while increasing anti-inflammatory IL-10 and IL-13. These effects were suppressed when animals were immunodepleted in macrophages. From a mechanistic point of view, the effect of L. reuteri GroEL seemed to involve TLR4, since it was lost in TRL4-/- mice, and the activation of a non-canonical TLR4 pathway. CONCLUSIONS: L. reuteri GroEL, by affecting macrophage inflammatory features, deserves to be explored as an alternative to probiotics.


Subject(s)
Chaperonin 60/pharmacology , Colon/drug effects , Inflammation/prevention & control , Lactobacillus/metabolism , Animals , Chaperonin 60/therapeutic use , Colon/physiopathology , Disease Models, Animal , Inflammation/drug therapy , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/metabolism , Mice, Inbred BALB C , Statistics, Nonparametric
4.
Microb Pathog ; 89: 27-34, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26318874

ABSTRACT

The purpose of this study was to evaluate the adjuvant effect of the B subunits of cholera toxin (CT) and the thermolabile enterotoxin of Escherichia coli (LT) by the intrarectal route of immunization and compare them to the whole molecules CT and LT-R192G, a non toxic mutant of LT, using 2/6-VLP as an antigen, in mice. All molecules induced similar antigen specific antibody titers in serum and feces, whereas different T cell profiles were observed. CTB and LTB, conversely to CT and LT-R192G, did not induce detectable production of IL-2 by antigen specific T cells. Moreover, CTB, conversely to LT-R192G, CT and LTB, did not induce antigen specific CD4+CD25+Foxp3- and Foxp3+ T cells, thus showing different effects between the B subunits themselves. However, all molecules induced an antigen specific Th17 response. In conclusion, B subunits are potent adjuvants on B cell responses by the intrarectal route. Although their impact on T cell responses are different, all molecules induce a 2/6-VLP-specific Th17 T cell response that may play a major role in helping B cell responses and thus in adjuvanticity and protection.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antibodies, Viral/blood , Bacterial Toxins/administration & dosage , Cholera Toxin/administration & dosage , Enterotoxins/administration & dosage , Escherichia coli Proteins/administration & dosage , Rotavirus Vaccines/immunology , Th17 Cells/immunology , Vaccines, Virus-Like Particle/immunology , Administration, Rectal , Animals , Antibodies, Viral/analysis , Antibody Formation , Feces/chemistry , Immunologic Memory , Interleukin-2/metabolism , Mice , Rotavirus Vaccines/administration & dosage , Vaccines, Virus-Like Particle/administration & dosage
5.
Vaccine ; 31(15): 1924-30, 2013 Apr 08.
Article in English | MEDLINE | ID: mdl-23453731

ABSTRACT

In this study, we compared both the profile and distribution of antigen specific primed T cells after intrarectal (IR) and intranasal (IN) immunization with rotavirus (RV) 2/6-VLP, alone or in the presence of LT-R192G, in order to highlight the differences between the two routes and the impact of the adjuvant. Adult BALB/c mice were immunized once with 2/6-VLP with or without adjuvant and the T cell response was analyzed in lymphoid tissues after in vitro restimulation with the antigen. IN, but not IR, immunization of mice with 2/6-VLP alone induced antigen-specific IL-10 and IL-17 secreting T cells. IL-10-, in contrast to IL-17-, secreting T cells did not migrate to the mesenteric lymph nodes (MLN) whereas they were detected in cervical lymph nodes (CLN) and spleen. With the IN route, the adjuvant allowed to complete this profile with the secretion of IL-2 and IL-4, increased IL-17 secretion and induced antigen specific CD4+CD25+Foxp3+ and Foxp3- T cells in all studied organs (CLN, spleen and MLN) but did not impact on IL-10 secreting T cells. With the IR route, the adjuvant induced IL-2 and IL-17 secretion but, in contrast to the IN route, did not allow IL-4 production. These results show that, for a same antigen, T cell priming not only depends on the presence of adjuvant but also on the mucosal route of administration. Moreover, they show a different dissemination of IL-10 secreting T cells compared to other subtypes.


Subject(s)
Antigens, Viral/immunology , Bacterial Toxins/immunology , Enterotoxins/immunology , Escherichia coli Proteins/immunology , Rotavirus Vaccines/administration & dosage , Rotavirus Vaccines/immunology , Rotavirus/immunology , T-Lymphocytes/immunology , Vaccines, Virus-Like Particle/immunology , Adjuvants, Immunologic , Administration, Intranasal , Administration, Rectal , Animals , B-Lymphocytes/immunology , Bacterial Toxins/administration & dosage , Cell Movement , Cross-Priming , Enterotoxins/administration & dosage , Escherichia coli Proteins/administration & dosage , Female , Immunity, Mucosal , Interleukins/immunology , Interleukins/metabolism , Lymphoid Tissue/immunology , Mice , Mice, Inbred BALB C , Rotavirus/drug effects , Rotavirus/physiology , Rotavirus Infections/immunology , Rotavirus Infections/prevention & control , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Vaccination , Vaccines, Virus-Like Particle/administration & dosage
6.
Toxins (Basel) ; 2(7): 1774-95, 2010 07.
Article in English | MEDLINE | ID: mdl-22069660

ABSTRACT

Cholera toxin (CT) and the heat-labile enterotoxin of E. coli (LT), as well as their non toxic mutants, are potent mucosal adjuvants of immunization eliciting mucosal and systemic responses against unrelated co-administered antigens in experimental models and in humans (non toxic mutants). These enterotoxins are composed of two subunits, the A subunit, responsible for an ADP-ribosyl transferase activity and the B subunit, responsible for cell binding. Paradoxically, whereas the whole toxins have adjuvant properties, the B subunits of CT (CTB) and of LT (LTB) have been shown to induce antigen specific tolerance when administered mucosally with antigens in experimental models as well as, recently, in humans, making them an attractive strategy to prevent or treat autoimmune or allergic disorders. Immunomodulation is a complex process involving many cell types notably antigen presenting cells and regulatory T cells (Tregs). In this review, we focus on Treg cells and cholera-like enterotoxins and their non toxic derivates, with regard to subtype, in vivo/in vitro effects and possible role in the modulation of immune responses to coadministered antigens.


Subject(s)
Bacterial Toxins/immunology , Cholera Toxin/immunology , Enterotoxins/immunology , Escherichia coli Proteins/immunology , T-Lymphocytes, Regulatory/immunology , Adjuvants, Immunologic , Animals , Autoimmune Diseases/immunology , Bacterial Toxins/chemistry , Cholera Toxin/chemistry , Enterotoxins/chemistry , Escherichia coli Proteins/chemistry , Humans , Immune Tolerance
7.
Toxins (Basel) ; 2(8): 2007-27, 2010 08.
Article in English | MEDLINE | ID: mdl-22069670

ABSTRACT

LT-R192G, a mutant of the thermolabile enterotoxin of E. coli, is a potent adjuvant of immunization. Immune responses are generally analyzed at the end of protocols including at least 2 administrations, but rarely after a prime. To investigate this point, we compared B and T cell responses in mice after one and two intrarectal immunizations with 2/6 rotavirus-like particles (2/6-VLP) and LT-R192G. After a boost, we found, an unexpected lower B cell expansion measured by flow cytometry, despite a secondary antibody response. We then analyzed CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) and CD4(+)CD25(+)Foxp3(-) helper T cells after in vitro (re)stimulation of mesenteric lymph node cells with the antigen (2/6-VLP), the adjuvant (LT-R192G) or both. 2/6-VLP did not activate CD4(+)CD25(+)Foxp3(-) nor Foxp3(+) T cells from non-immunized and 2/6-VLP immunized mice, whereas they did activate both subsets from mice immunized with 2/6-VLP in the presence of adjuvant. LT-R192G dramatically decreased CD4(+)CD25(+)Foxp3(+) T cells from non-immunized and 2/6-VLP immunized mice but not from mice immunized with 2/6-VLP and adjuvant. Moreover, in this case, LT-R192G increased Foxp3 expression on CD4(+)CD25(+)Foxp3(+) cells, suggesting specific Treg activation during the recall. Finally, when both 2/6-VLP and LT-R192G were used for restimulation, LT-R192G clearly suppressed both 2/6-VLP-specific CD4(+)CD25(+)Foxp3(-) and Foxp3(+) T cells. All together, these results suggest that LT-R192G exerts different effects on CD4(+)CD25(+)Foxp3(+) T cells, depending on a first or a second contact. The unexpected immunomodulation observed during the recall should be considered in designing vaccination protocols.


Subject(s)
Adjuvants, Immunologic/pharmacology , B-Lymphocytes/immunology , Bacterial Toxins/pharmacology , Enterotoxins/pharmacology , Escherichia coli Proteins/pharmacology , Immunization , Rotavirus Vaccines/immunology , T-Lymphocytes/immunology , Virion/immunology , Animals , Dose-Response Relationship, Immunologic , Female , Mice , Mice, Inbred BALB C
8.
J Infect Dis ; 200(10): 1574-82, 2009 Nov 15.
Article in English | MEDLINE | ID: mdl-19832116

ABSTRACT

Increasing antibiotic resistance has prompted development of alternative approaches to antimicrobial therapy, including blocking microbial adhesion to host receptors. The BabA adhesin of Helicobacter pylori binds to fucosylated blood group antigens, such as the Lewis(b) antigens in human primate gastric mucosa. We have isolated a human domain antibody specific for BabA that inhibits binding of BabA to Lewis(b) and prevents adhesion of H. pylori to human gastric epithelium. In addition, Lewis(b) oligosaccharides covalently linked to poly-D-lysine inhibited BabA binding to Le(b). The poly-D-lysine-Le(b) hexasaccharide and an Le(b) human serum albumin conjugate not only inhibited adherence of H. pylori to gastric epithelium but also displaced adherent bacteria when added to human stomach sections. Combinations of Le(b) and sialyl Le(x) or domain antibody 25 and sialyl Le(x) acted synergistically. Domain antibody 25 inhibitor may have potential for prophylactic use and, in combination with Le(b) glycoconjugates, therapeutic use in treatment of drug-resistant H. pylori infection.


Subject(s)
Adhesins, Bacterial/immunology , Helicobacter Infections/immunology , Helicobacter pylori/immunology , Immunoglobulin Variable Region/immunology , Lewis Blood Group Antigens/immunology , Antibody Specificity , Gastric Mucosa/immunology , Gastric Mucosa/microbiology , Humans , Immunization, Passive , In Vitro Techniques , Stomach/immunology , Stomach/microbiology
9.
J Leukoc Biol ; 82(4): 821-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17652448

ABSTRACT

Selection of mucosal sites is an important step in mucosal vaccine development. The intrarectal (IR) route represents an alternative to the oral route of immunization; nevertheless, immune responses induced by this route are not well defined. Here, we studied the early primary B cell response (induction, homing, and phenotype) induced by IR immunization with rotavirus (RV)-2/6 virus-like particles (VLP). Using flow cytometry, we traced RV-specific B cells in different lymphoid tissues and analyzed the expression of alpha4beta7 and CCR9, which are important receptors for homing to the gut, as well as CD5, a marker expressed by B1-a cells, which are a major source of natural antibodies. We observed a massive, specific B cell response in rectal follicles, lumbar, and mesenteric lymph nodes but not in Peyer's patches or cervical lymph nodes. A minority of cells expressed alpha4beta7, suggesting a probable lack of migration to the gut, whereas CCR9 and CD5 were expressed by 30-50% and 30-75% of specific B cells, respectively. Then, we compared the intranasal route of immunization and observed similar B cell frequency and phenotype but in respiratory lymphoid tissues. These results confirm the high compartmentalization of B cell responses within the mucosal system. They show that CCR9 expression, conversely to alpha4beta7, is not restricted to B cells induced in the gut. Finally, an important part of the RV-specific B cell response induced at the mucosal level during the primary response to VLP is most likely a result of B1-a cells.


Subject(s)
Antigens, Viral/immunology , B-Lymphocytes/immunology , Cell Movement/immunology , Immunity, Mucosal , Rotavirus Vaccines/immunology , Rotavirus/immunology , Administration, Intranasal , Animals , Antibodies, Viral/immunology , Antigens, Viral/administration & dosage , CD5 Antigens/immunology , Cell Movement/drug effects , Female , Immunity, Mucosal/drug effects , Immunization , Intestines/immunology , Lumbosacral Region , Lymph Nodes/immunology , Mesentery/immunology , Mice , Mice, Inbred BALB C , Peyer's Patches , Phenotype , Receptors, CCR/immunology , Receptors, Lymphocyte Homing/immunology , Rotavirus Vaccines/administration & dosage
10.
J Hepatol ; 44(3): 552-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16310277

ABSTRACT

BACKGROUND/AIMS: Dendritic cells (DCs), which play a critical role during immune response, could present alternative differentiation patterns depending on tissue microenvironment. Our aim was to examine the influence of hepatic microenvironment on human monocyte differentiation into DCs. METHODS: Cytology, immunophenotyping, cytokine production and T-cell activation were analyzed in DCs differentiated from human monocytes co-cultured with rat liver epithelial cells (RLEC) or human cells from various tissue origins and compared to control DCs obtained on plastic with GM-CSF/IL-4. RESULTS: RLEC environment promotes DC differentiation in the presence of IL-4 without GM-CSF. These DCs evidence similar expression of MHC-II, co-stimulatory and adhesion molecules than control DCs, but distinct lineage markers defining a CD11c+/CD14+/CD123+ DC subset. This phenotype is common to DCs from RLEC and human liver environment and differs from that obtained with skin or intestine environments. Functionally, they produce IL-10 but not IL-12p70 and favor IL-4/IL-10 secretion by T-cells rather than IFN-gamma. CONCLUSIONS: Our results confirm that tissue niches modulate DC differentiation and demonstrate that hepatic environment influences monocyte differentiation into a DC subset directing Th2 response, a key data for understanding the specialized immune response in liver. They also make RLEC co-culture system useful for studying liver DC functions.


Subject(s)
Cell Differentiation , Dendritic Cells/cytology , Immunity, Cellular , Liver/immunology , Monocytes/cytology , Th2 Cells/immunology , Animals , Cells, Cultured , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , In Vitro Techniques , Interleukin-10/metabolism , Interleukin-4/pharmacology , Liver/cytology , Liver/metabolism , Monocytes/drug effects , Monocytes/metabolism , Phenotype , Rats , Th2 Cells/cytology , Th2 Cells/metabolism
11.
J Microbiol Methods ; 61(1): 105-26, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15676201

ABSTRACT

We have compared current image analysis software packages in order to find the most useful one for assessing microbial adhesion and inhibition of adhesion to tissue sections. We have used organisms of different sizes, the bacterium Helicobacter pylori and the yeast Candida albicans. Adhesion of FITC-labelled H. pylori and C. albicans was assessed by confocal microscopy. Four different Image analysis software packages, NIH-Image, IP Lab, Image Pro+, and Metamorph, were compared for their ability to quantify adhesion of the two organisms and several quantification methods were devised for each package. For both organisms, the dynamic range that could be detected by the software packages was 1x10(6)-1x10(9) cells/ml. Of the four software packages tested, our results showed that Metamorph software, using our 'Region of Interest' method, with the software's 'Standard Area Method' of counting, was the most suitable for quantifying adhesion of both organisms because of its unique ability to separate clumps of microbial cells. Moreover, fewer steps were required. By pre-incubating H. pylori with the glycoconjugate Lewis b-HSA, an inhibition of binding of 48.8% was achieved using 250 mug/ml Lewis b-HSA. The method we have devised using Metamorph software, provides a simple, quick and accurate way of quantifying adhesion and inhibition of adhesion of microbial cells to the epithelial surface of tissue sections. The method can be applied to organisms ranging in size from small bacteria to larger yeast cells.


Subject(s)
Bacterial Adhesion/physiology , Candida albicans/physiology , Candidiasis/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/physiology , Image Processing, Computer-Assisted/methods , Stomach Diseases/microbiology , Vaginal Diseases/microbiology , Animals , Female , Humans , Image Processing, Computer-Assisted/standards , Microscopy, Confocal , Rats , Software/standards
12.
World J Gastroenterol ; 11(47): 7499-507, 2005 Dec 21.
Article in English | MEDLINE | ID: mdl-16437723

ABSTRACT

AIM: To investigate the bactericidal and anti-adhesive properties of 25 plants against Helicobacter pylori (H. pylori). METHODS: Twenty-five plants were boiled in water to produce aqueous extracts that simulate the effect of cooking. The bactericidal activity of the extracts was assessed by a standard kill-curve with seven strains of H. pylori. The anti-adhesive property was assessed by the inhibition of binding of four strains of FITC-labeled H. pylori to stomach sections. RESULTS: Of all the plants tested, eight plants, including Bengal quince, nightshade, garlic, dill, black pepper, coriander, fenugreek and black tea, were found to have no bactericidal effect on any of the isolates. Columbo weed, long pepper, parsley, tarragon, nutmeg, yellow-berried nightshade, threadstem carpetweed, sage and cinnamon had bactericidal activities against H. pylori, but total inhibition of growth was not achieved in this study. Among the plants that killed H. pylori, turmeric was the most efficient, followed by cumin, ginger, chilli, borage, black caraway, oregano and liquorice. Moreover, extracts of turmeric, borage and parsley were able to inhibit the adhesion of H. pylori strains to the stomach sections. CONCLUSION: Several plants that were tested in our study had bactericidal and/or anti-adhesive effects on H. pylori. Ingestion of the plants with anti-adhesive properties could therefore provide a potent alternative therapy for H. pylori infection, which overcomes the problem of resistance associated with current antibiotic treatment.


Subject(s)
Bacterial Adhesion/drug effects , Helicobacter Infections/prevention & control , Helicobacter pylori/drug effects , Plants, Medicinal , Spices , Anti-Bacterial Agents/pharmacology , Biopsy , Cooking , Helicobacter pylori/growth & development , Humans , In Vitro Techniques , Stomach/cytology , Stomach/microbiology
13.
Dig Dis Sci ; 49(9): 1425-32, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15481314

ABSTRACT

The aim of this study was to determine if either Helicobacter or enterotoxigenic Bacteroidesfragilis (ETBF) was linked to inflammatory bowel disease (IBD), using PCR. We analyzed the luminal washings and colonic biopsies of 35 patients with IBD and 37 control patients. The presence of Helicobacter was confirmed in the luminal washing of one IBD patient and three control patients and in the biopsies of two IBD patients. Ten of 28 control patients and 8 of 32 IBD patients had a positive luminal washing for the enterotoxin gene. Six of 33 control patients and 4 of 32 IBD patients had positive biopsies. The prevalence of the enterotoxin gene was higher in IBD patients with active disease compared with patients with inactive disease, although it did not achieve statistical significance. In conclusion, Helicobacter was not associated with IBD in our population of patients, although ETBF may be associated with active disease.


Subject(s)
Bacteroides Infections/diagnosis , Bacteroides fragilis/isolation & purification , Helicobacter Infections/diagnosis , Helicobacter pylori/isolation & purification , Inflammatory Bowel Diseases/microbiology , Adult , Age Distribution , Aged , Aged, 80 and over , Bacteroides Infections/epidemiology , Base Sequence , Case-Control Studies , Chi-Square Distribution , DNA, Bacterial/analysis , Female , Helicobacter Infections/epidemiology , Humans , Incidence , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/epidemiology , Male , Middle Aged , Molecular Sequence Data , Odds Ratio , Polymerase Chain Reaction/methods , Probability , Risk Assessment , Sex Distribution
14.
Sci Prog ; 87(Pt 4): 269-96, 2004.
Article in English | MEDLINE | ID: mdl-16028836

ABSTRACT

Helicobacter pylori is a global pathogen that causes severe gastrointestinal diseases leading to a significant morbidity and mortality. There is an effective treatment for peptic ulcer disease, however, this is being compromised by an increase in the prevalence of antibiotic resistance. Although alternative rescue regimens have been advocated, the best strategy would be to prevent disease, especially in the case of gastric cancer for which there is still no treatment. One approach is to inhibit the first step in the pathogenic process - adhesion of the organism to the host tissue. Another and probably a better approach is vaccination, but clinical trials have so far been unsuccessful. There is still a large uncertainty in relation to how H. pylori causes disease. Knowledge from genomics, proteomics, and the relationship between polymorphism of the bacterium and the host, as well as the continuing investigation of the role played by important virulence factors in the outcome of the disease, will help both in understanding pathogenesis of disease and in the design of the best vaccine.


Subject(s)
Helicobacter pylori/pathogenicity , Animals , Anti-Infective Agents/pharmacology , Antigens, Bacterial/physiology , Bacterial Adhesion , Bacterial Proteins/physiology , Epithelium/microbiology , Genome, Bacterial , Helicobacter pylori/genetics , Helicobacter pylori/metabolism , Helicobacter pylori/physiology , Humans , Peptic Ulcer/microbiology , Polymerase Chain Reaction , Proteome , Stomach Neoplasms/microbiology
15.
Vaccine ; 21 Suppl 2: S12-23, 2003 Jun 01.
Article in English | MEDLINE | ID: mdl-12763678

ABSTRACT

The skin and contiguous mucosal surfaces define the primary locus of interaction between host and micro-organisms. In this review, we focus on the innate immune system in the mucosa, which manages to deal with invading pathogens, the mechanisms that organisms have evolved in order to circumvent this primary defensive barrier and, finally, potential therapeutic manipulation of the innate immune system that was the focus of meeting at a Euroconference/Workshop on "Novel Strategies of Mucosal Immunisation through Exploitation of Mechanisms of Innate Immunity in Pathogen-Host Interaction", which was held in Siena, Italy, November 2002.


Subject(s)
Immunity, Innate , Immunity, Mucosal , Animals , Chemokines/physiology , Collectins/physiology , Complement System Proteins/physiology , Cytokines/physiology , Dendritic Cells/physiology , Humans , Killer Cells, Natural/immunology , Mast Cells/physiology , Membrane Glycoproteins/physiology , Neutrophils/immunology , Receptors, Cell Surface/physiology , Signal Transduction/physiology , Toll-Like Receptors
16.
Sci Prog ; 85(Pt 1): 13-31, 2002.
Article in English | MEDLINE | ID: mdl-11969117

ABSTRACT

There are many diseases where the cause is unknown and this makes a specific treatment difficult. In many cases all that can be achieved is amelioration of the illness. Peptic ulcer disease was one such condition no more that 20 years ago. The management was drastic--either an operation or life-long medication in order to reduce the acid secreted by the stomach. However, the cause of this condition was discovered in 1983. Although initially sceptical, the medical fraternity now almost universally endorse Helicobacter pylori as the cause of the majority of stomach ulcers. Peptic ulcers can now be cured by antibiotics. This is a major shift in medical practice. Continued investigations on Helicobacter pylori are bringing to light other possible associations with disease as well as delineating plausible biological mechanisms for disease pathogenesis.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Peptic Ulcer/microbiology , Autoantibodies/physiology , Cell Communication/physiology , Cell Cycle/physiology , Cytotoxins/physiology , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Helicobacter Infections/transmission , Helicobacter pylori/pathogenicity , Helicobacter pylori/physiology , Humans , Peptic Ulcer/complications , Peptic Ulcer/diagnosis , Peptic Ulcer/drug therapy , Stomach Neoplasms/etiology
17.
Sci Prog ; 85(Pt 1): 33-56, 2002.
Article in English | MEDLINE | ID: mdl-11969118

ABSTRACT

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the intestines that is clinically heterogenous. The cause(s) of IBD are currently unknown but the mechanisms of injury are immunological. Increasingly there is an emphasis on the study of the complex interactions at the interface of self and non-self--the gastrointestinal epithelial surface--in relationship to the pathogenesis of disease. There is mounting evidence that a lack of tolerance to the normal commensal flora of the intestine may underlie the disease pathogenesis. Several genetic loci that are markers of disease susceptibility have been identified. These loci map to areas of the genome that are concerned with antigen presentation or cytokine secretion and suggest a genetic heterogeneity that underlies the clinical differences. Overall a picture is emerging of defects in epithelial barrier function and, or immunoregulation leading to immune responses that are triggered or exaggerated by the antigenic components of the normal flora.


Subject(s)
Inflammatory Bowel Diseases/immunology , Intestines/immunology , Epithelium/immunology , Epithelium/metabolism , Genetic Predisposition to Disease , Humans , Immunity, Cellular , Immunity, Mucosal , Immunoglobulin A, Secretory/physiology , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/microbiology , Intestinal Mucosa/immunology , Intestinal Mucosa/microbiology , Intestines/microbiology , Lymphoid Tissue/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...